CN117043191A - 糖蛋白vi的纳米抗体 - Google Patents
糖蛋白vi的纳米抗体 Download PDFInfo
- Publication number
- CN117043191A CN117043191A CN202180094483.4A CN202180094483A CN117043191A CN 117043191 A CN117043191 A CN 117043191A CN 202180094483 A CN202180094483 A CN 202180094483A CN 117043191 A CN117043191 A CN 117043191A
- Authority
- CN
- China
- Prior art keywords
- ser
- gly
- ala
- tyr
- val
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2020602.5A GB202020602D0 (en) | 2020-12-24 | 2020-12-24 | Nanobody |
| GB2020602.5 | 2020-12-24 | ||
| PCT/EP2021/087129 WO2022136457A1 (en) | 2020-12-24 | 2021-12-21 | Nanobody to glycoprotein vi |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117043191A true CN117043191A (zh) | 2023-11-10 |
Family
ID=74532190
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180094483.4A Pending CN117043191A (zh) | 2020-12-24 | 2021-12-21 | 糖蛋白vi的纳米抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240067721A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4267624A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024500946A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117043191A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3203202A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB202020602D0 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022136457A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026019685A1 (en) * | 2024-07-17 | 2026-01-22 | Harpoon Therapeutics, Inc. | Her2 targeting trispecific protein for treatment of cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0130543D0 (en) * | 2001-12-20 | 2002-02-06 | Univ Cambridge Tech | Human antibodies and their use |
| US20090130021A1 (en) * | 2002-06-07 | 2009-05-21 | Gotz Munch | Methods, products and uses involving platelets and/or the vasculature |
| WO2007091719A1 (ja) * | 2006-02-07 | 2007-08-16 | Mochida Pharmaceutical Co., Ltd. | 抗gpvi抗体の併用療法及び新規医薬用途 |
| EP1916259A1 (en) * | 2006-10-26 | 2008-04-30 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Anti-glycoprotein VI SCFV fragment for treatment of thrombosis |
| JP5843783B2 (ja) * | 2009-12-18 | 2016-01-13 | サノフイ | GPVIに対する新規アンタゴニスト抗体および該抗体のFabフラグメントならびにこれらの使用 |
-
2020
- 2020-12-24 GB GBGB2020602.5A patent/GB202020602D0/en not_active Ceased
-
2021
- 2021-12-21 WO PCT/EP2021/087129 patent/WO2022136457A1/en not_active Ceased
- 2021-12-21 CN CN202180094483.4A patent/CN117043191A/zh active Pending
- 2021-12-21 US US18/269,308 patent/US20240067721A1/en active Pending
- 2021-12-21 EP EP21844966.8A patent/EP4267624A1/en active Pending
- 2021-12-21 JP JP2023538767A patent/JP2024500946A/ja active Pending
- 2021-12-21 CA CA3203202A patent/CA3203202A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4267624A1 (en) | 2023-11-01 |
| WO2022136457A1 (en) | 2022-06-30 |
| US20240067721A1 (en) | 2024-02-29 |
| CA3203202A1 (en) | 2022-06-30 |
| JP2024500946A (ja) | 2024-01-10 |
| GB202020602D0 (en) | 2021-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7047017B2 (ja) | 黄色ブドウ球菌(Staphylococcus aureus)α毒素に特異的に結合する抗体及び使用方法 | |
| KR102700015B1 (ko) | 개선된 저장 및 투여를 위한 이중특이적 항체 구축물을 포함하는 약제학적 조성물 | |
| KR102914586B1 (ko) | 메소텔린 및 cd3에 결합하는 이중특이적 항체 작제물 | |
| KR102735615B1 (ko) | Egfrviii 및 cd3에 결합하는 이중특이적 항체 작제물 | |
| JP6693872B2 (ja) | 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法 | |
| US9045538B2 (en) | Anti-glycoprotein VI scFv fragment for treatment of thrombosis | |
| JP7785450B2 (ja) | Muc17及びcd3に向けられる二重特異性抗体コンストラクト | |
| KR20260028110A (ko) | 이중특이성 t 세포 맞물림 항체 작제물 | |
| CN106163556A (zh) | 基质金属蛋白酶底物和其它可切割部分及其使用方法 | |
| US12617863B2 (en) | Humanized anti-glycoprotein Ib alpha (GPIbalpha) antibodies | |
| US11542329B2 (en) | Antibodies targeting Glycoprotein VI | |
| US20240067721A1 (en) | Nanobody to glycoprotein vi | |
| US20240247076A1 (en) | Coagulation factor xi (fxi) binding protein | |
| CN107614524A (zh) | 治疗 | |
| HK40108701A (en) | Antibody constructs for msln and cd3 | |
| HK40038870B (en) | Humanized anti-glycoprotein ib alpha antibodies and use thereof | |
| HK40038870A (en) | Humanized anti-glycoprotein ib alpha antibodies and use thereof | |
| HK1191977A (en) | Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use | |
| HK1191977B (en) | Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |